IDS And Amendments Filed After Final Rejection Presented By:Steven P. Scuderi Pepe & Hazard LLP Pepe & Hazard LLP.

Slides:



Advertisements
Similar presentations
Final Office Action Practice
Advertisements

1 Pre-Appeal Brief Conference (with Demo) By: Bennett Celsa Jean Witz Kathleen Bragdon TC1600 Quality Assurance Specialists.
The Examination Process
Incorporation by Reference
Comments on the USPTO’s Proposed Streamlined Patent Reexamination Regulations Greg H. Gardella Elizabeth Iglesias Jason Sullivan Irell & Manella, LLP.
Michael Neas Supervisor Office of PCT Legal Administration
Accelerating Patent Prosecution Thursday, October 18, 2012.
Update on USPTO Activities November 18, 2014 Drew Hirshfeld Deputy Commissioner for Patent Examination Policy 1.
USPTO Madrid Protocol Seminar on Tips for Filing International Applications and Maintaining International Registrations MPU Review of International Application.
Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting October 8, 2002 William F. Smith Administrative Patent Judge Board of Patent Appeals.
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the “Notes” Tab. Claim Interpretation: Broadest Reasonable.
1 1 1 AIPLA American Intellectual Property Law Association USPTO Updates Including Glossary Pilot Program Chris Fildes Fildes & Outland, P.C. IP Practice.
PROSECUTION APPEALS Presented at: Webb & Co. Rehovot, Israel Date: February 14, 2013 Presented by: Roy D. Gross Associate St. Onge Steward Johnston & Reens.
1 1 AIPLA American Intellectual Property Law Association RCE Practice: Pilot Programs and Delays in Examination Chris Fildes Fildes & Outland, P.C. IP.
September 14, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December.
Robert M. Hansen The Marbury Law Group PLLC AIPLA Practical Patent Prosecution Training for New Lawyers August 2009Alexandria, VA Issuance, Term, Certificates.
America Invents Act (AIA) Changes in Patent Law That Impact Companies May Mowzoon: Mowzoon Law Office, PLLC 1.
Filing Compliant Reexam Requests Andy Kashnikow SPE, Central Reexamination Unit Andy Kashnikow SPE, Central Reexamination Unit June, 2010.
Enhanced First Action Interview (EFAI) Pilot Program Wendy Garber Tech Center Director, 2100 United States Patent & Trademark Office.
TC1600 Appeals Practice Jean Witz, Appeals Specialist.
July 8, Enhanced Examination Timing Control Robert A. Clarke Deputy Director Office of Patent Legal Administration
Accelerated Examination Bennett Celsa (TC 1600: QAS)
Patent Term Adjustment (Bio/Chem. Partnership) Kery Fries, Sr. Legal Advisor Phone: (571)
by Eugene Li Summary of Part 3 – Chapters 8, 9, and 10
Appeal Practice Refresher Office of Patent Training.
AIA Strategies.
July 18, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818/P.L ) Topic: Patent Fees Office of Patent Legal.
September 14, Final Rule Making on Practice Before the Board of Patent Appeals and Interferences (BPAI) Robert Spar Director of the Office of Patent.
Information Disclosure Statements
Ashok K. Mannava Mannava & Kang, P.C. Expedited Examination Programs from the PTO February 12, 2012.
December 8, Changes to Patent Fees Under the Consolidated Appropriations Act, 2005 (H.R. 4818)(upon enactment) and 35 U.S.C. 103(c) as Amended by.
February 19, Recent Changes and Developments in USPTO Practice Prepared by: Office of Patent Legal Administration (OPLA) Robert J. Spar, DirectorJoni.
1 AIPLA Biotech Committee Meeting Washington D.C., October 14, 2004 Anthony Caputa, Ph.D. Technology Center Practice Specialist TC 1600.
Remy Yucel Director, CRU (571) Central Reexamination Unit and the AIA.
Restriction & Double Patenting Mojdeh Bahar, J.D., M.A., CLP Chief, Cancer Branch Office of Technology Transfer National Institutes of Health U.S. Department.
November 29, Global Intellectual Property Academy Advanced Patents Program Kery Fries, Senior Legal Advisor Mark Polutta, Senior Legal Advisor Office.
1 LAW DIVISION PATENT DIVISION TRADEMARK & DESIGN DIVISION ACCOUNTING & AUDITING DIVISION YUASA AND HARA LAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING.
July 18, U.S.C. 103(c) as Amended by the Cooperative Research and Technology Enhancement (CREATE) Act (Public Law ) Enacted December 10,
Post-Grant & Inter Partes Review Procedures Presented to AIPPI, Italy February 10, 2012 By Joerg-Uwe Szipl Griffin & Szipl, P.C.
Practice Before the U.S. Patent and Trademark Office Board of Patent Appeals and Interferences.
Prosecution Lunch Patents January Reminder: USPTO Fee Changes- Jan. 1, 2014 Issue Fee Decrease- delay paying if you can –Issue Fee: from $1,780.
BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. Patent.
1 Rules of Practice Before the BPAI in Ex Parte Appeals 73 Fed. Reg (June 10, 2008) Effective December 10, Fed. Reg (June 10, 2008)
Patent Prosecution Luncheon February Defective Priority Claim Means No Priority Claim Each intermediate application in the chain of priority must.
Reexamination at the USPTO Robert A. Clarke Deputy Director Office of Patent Legal Administration USPTO Robert A. Clarke Deputy Director Office of Patent.
Claims and Continuations Final Rule Overview Briefing for Examiners 1.
Patent Prosecution May PCT- RCE Zombie 371 National Stage PCT Applications –Not Allowed to file an RCE until signed inventor oath/declaration is.
New Ex Parte Appeal Rules Patent and Trademark Practice Group Meeting January 26, 2012.
3 rd Party Participation Bennett Celsa TC 1600 QAS.
© COPYRIGHT DICKSTEIN SHAPIRO LLP. ALL RIGHTS RESERVED. Post Grant Proceedings Before the USPTO and Litigation Strategies Under the AIA Panelists:David.
QualityDefinition.PPACMeeting AdlerDraft 1 1 Improving the Quality of Patents Marc Adler PPAC meeting June 18, 2009.
Claims and Continuations Final Rule 1 Joni Y. Chang Senior Legal Advisor Office of Patent Legal Administration (571) ,
FY09 Restriction Petition Update; Comparison of US and National Stage Restriction Practice Julie Burke TC1600 Quality Assurance Specialist
Chris Fildes FILDES & OUTLAND, P.C. IP Practice in Japan Committee Pre-Meeting AIPLA Annual Meeting, October 20, 2015 USPTO PILOT PROGRAMS 1 © AIPLA 2015.
James Toupin – General Counsel February 1, Summary of Proposed Rule Changes to Continuations, Double Patenting, and Claims.
Patent Fee Proposal Patent Public Advisory Committee Hearing November 19, 2015.
Claims Proposed Rulemaking Main Purposes É Applicant Assistance to Improve Focus of Examination n Narrow scope of initial examination so the examiner is.
Prosecution Group Luncheon Patent October PTO News Backlog of applications continues to decrease –623,000 now, decreasing about 5,000/ month –Expected.
Andrew B. Freistein Wenderoth, Lind & Ponack, L.L.P. Learning the ABC’s of Patent Term Adjustment 1 © AIPLA 2015.
January 25, Notice of Proposed Rule Making Proposed Changes to Practice for Continuing Applications, Requests for Continued Examination Practice,
Double Patenting Deborah Reynolds SPE Art Unit 1632 Detailee, TC1600 Practice Specialist
Report to the AIPLA’s IP Practice in Japan Committee January 22, 2012 USPTO Appeal Process: Appeal Strategies and New Rules Presented by: Stephen S. Wentsler.
USPTO Madrid Protocol Seminar on Tips for Filing International Applications and Maintaining International Registrations Miscellaneous Issues October 23,
PTAB Litigation 2016 Part 6 – Patent Owner Response 1.
Prosecution Luncheon Patent August 2016
Pre-Issuance (Third-Party) Submissions
Claims and Continuations Final Rule
USPTO Appeal Process: Appeal Strategies and New Rules
PATENT LAW TREATY Gena Jones Senior Legal Advisor
Third Party Pre-Issuance Submissions Under AIA
Presentation transcript:

IDS And Amendments Filed After Final Rejection Presented By:Steven P. Scuderi Pepe & Hazard LLP Pepe & Hazard LLP

Final Rejection: 37 CFR I)On the second or any subsequent action, an Examiner can make an action final when: A)The Examiner repeats a rejection previously made; or B)Makes a rejection which was necessitated by an action of the applicant. II)A final rejection is not literally “final”; rather it establishes a restrictive set of rules which govern what the applicant can do and how prosecution or appeal can be continued. 2

Reply To Final Rejection: 37 CFR I)A reply under 37 CFR is limited to: A)An amendment complying with 37 CFR 1.116; B)A Notice of Appeal (and appeal fee); or C)A request for continued examination (RCE) filed under 37 CFR with a submission, i.e., an amendment that meets the reply requirement of 37 CFR 1.111, and the fee set forth in 37 CFR. II)Failure to properly reply under 37 CFR to the final rejection results in abandonment. III)Alternatively, a continuation or CIP can be filed and the original case can be abandoned. 3

Amendments After Final Action Or Appeal: 37 CFR (a)An Amendment after final action or appeal must comply with Section or this section. (b)After a final rejection or other final action (Section 1.113) in an application or in an ex parte re-examination filed under Section 1.510, or an action closing prosecution (Section 1.949) in an inter partes re-examination filed under Section 1.913, amendments may be made canceling claims or complying with any requirement of form expressly set forth in a previous Office Action. Amendments presenting rejected claims in better form for consideration on appeal may be admitted. The admission of, or refusal to admit, any amendment after a final rejection, a final action, an action closing prosecution, or any related proceedings will not operate to relieve the application or patent under re-examination from its condition as subject to appeal or to save the application from abandonment under Section 1.135, or the re-examination from termination. No amendment can be made in an inter partes re-examination proceeding after the right of appeal notice under Section except as provided for in paragraph (d) of this section. (c)If amendments touching the merits of the application or patent under re-examination are presented after final rejection, or after appeal has been taken, or when such amendment might not otherwise be proper, they may be admitted upon a showing of good and sufficient reasons why they are necessary and were not earlier presented. (d)No amendment can be made as a matter of right in appealed cases. After decision on appeal, amendments can only be made as provided in Sections and 1.981, or to carry into effect a recommendation under Section or Section

Amendments Permitted Under 37 CFR 1.116(b) I)Amendments may be entered under 1.116(b) only if: A) They will place the application in condition for allowance; B) In better form for appeal; or C)Are to comply with objections or requirements as to form. II)Ordinarily, amendments filed after the final action are not entered unless approved by the Examiner. See, MPEP Section (f), Section and Section

Amendments Not A Matter Of Right: 37 CFR 1.116(c) I)Amendments “touching the merits of the application,” are not a matter of right, including: A)Amending any finally rejected claims; B)Adding new claims; or C)Reinstating previously canceled claims under Section 1.116(c). II) A showing of good and sufficient reasons why they are necessary and were not earlier presented. 6

III) A refusal to permit such an amendment is not a rejection on the merits and leaves the application in the same status it was in after the final rejection. IV)Allowance of amendments after final rejection is a matter of discretion and the remedy therefrom is a petition to the Commissioner under Rule 181. In RE: Berger, 61 USPQ2d 1523 (CA FC 1/29/2002). Amendments Not A Matter Of Right: 37 CFR 1.116(c) (continued) 7

Genzyme Corp. v. Transkaryotic Therapies, Inc., 68 USPQ2d 1596 (CA FC 10/9/2003) I)Ruling: Amendments made to claims after final rejection cannot alter substantive scope of claims without explanation regarding necessity of amendment and reasons for delay in proposing change. II)Facts: A) Infringement case involving a method of producing a human enzyme; B)Language for an amendment after final was accepted by the Examiner during an Examiners interview; C)The record did not explain the reasons the Examiner accepted the language; and D)Genzyme argued that the amendment after final broadened the scope of the claims. 8

Genzyme Corp. v. Transkaryotic Therapies, Inc., 68 USPQ2d 1596 (CA FC 10/9/2003) (continued) III)Court’s analysis: A)According to PTO rules (37 CFR 1.116), the Examiner could not accept supplemental amendment broadening scope of claims without formal comment from applicants; and B)Accordingly, the Examiner could not have allowed this amendment if it changed at all the scope of the claims set forth in the prior prosecution history. 9

Conflicts Between Amendments After Final And The Second Eye Review 10 I)On March 29, 2000, the USPTO announced an Action Plan for business method patents to improve the quality of the examination process in technologies related to electronic commerce and business methods, i.e., in Class 705. II)Second Eye Review: A new second-level review of all allowed applications in Class 705 is now required. A)Not a full re-examination; and B)Purpose to ensure compliance with search requirements, reasons for allowance and a determination as to whether the scope of claims should be reconsidered.

Conflicts Between Amendments After Final And The Second Eye Review (continued) III)Second Eye Reviews take extra time and can often extend past the 6 month deadline for reply. 11 A)110 Patent Examiners in Class 705. Only 2 to 4 Examiners for Second Eye Reviews; B)Approximately 500 issued patents in Class 705 in 2003; C)Can still take 3 to 4 months for a Second Eye Review; and D)Amendments after final alone are not considered an official reply and do not toll the deadline for abandonment.

War Story 12 I)May 6, 2003: Final Office Action issued by USPTO. Only rejection was for obvious-type double patenting. II)May 20, 2003: Filed a terminal disclaimer. III)August 4, 2003: Contacted Examiner. Informed of allowance and Second Eye Review. Examiner said that the process could take up to 6 months. IV)Early November 2003: Filed a Notice of Appeal to prevent the application from going abandoned.

War Story (continued) 13 VI)End of December 2003: Filed a petition to request a refund of fees spent due to keeping the application from going abandoned in view of the undue delays at the USPTO. VII)Early January 2004: Became necessary to file an Appeal Brief on behalf of the client. V)Late November 2003: Informed that new prior art had been discovered and that a new, non-final Office Action would be issued in the near future.

Recommendations I)Check to see if you have to be in Class 705. II)File an RCE with the Amendment After Final on any final rejection in Class 705. A)Removes finality of the action; B)Amendments become a matter of right; and C)Tolls the 6 month deadline date. 14 III)File a Notice of Appeal with an Appeal Brief with the Amendment After Final. A)May be less expensive than the RCE to file; B)Will not avoid the Second Eye Review; and C)Will extend the prosecution time.

Recommendations (continued) IV)If getting close to the 6 month deadline date, call the Examiner and request that the Second Eye Review be expedited, i.e., taken out of order. A)Do not have to file a petition to make special as in a normal review; B)Informal process and discretionary with the Examiner; and C)Examiners want to expedite the Second Eye Review. 15

Related Problems With Amendments And/Or IDS Filed After Notice Of Allowance I)How the system works in theory: A)If an application is in paper form, than after a Notice of Allowance, the application is mailed to the off-site Publication Branch Data Capture Facility (Pubs); B)If an IDS and/or amendment is filed after the application is mailed to Pubs, the application is returned to the Examiner for consideration upon request; C)If the application is filed as an Image File Wrapper (IFW) file in the USPTO electronic database, the IDS or amendment is scanned into the IFW file and a message is sent to the Examiner; and D)The Examiner can view the whole IFW file at anytime from their desktop. 16

17 Related Problems With Amendments And/Or IDS Filed After Notice Of Allowance (continued) II)Problems with the system in practice: A)Examiners sometimes have difficulty obtaining paper application files in a timely fashion once it has been mailed to Pubs; B)The issue fee must be paid within 3 months from the date of the NOA or the case is abandoned; and C)The case could issue without the IDS being considered. III)Recommendations: A)File an RCE before paying the issue fee.

B)Problem is only a temporary one: Related Problems With Amendments And/Or IDS Filed After Notice Of Allowance (continued) i)All pending paper applications are now being scanned into IFW database as soon as an action is generated from the applicant on the case, e.g., IDS, amendment, response to an Office Action; ii)Once scanned, a message is sent to the Examiner indicating that a reply is required; and iii) Should effectively eliminate problem in about 2 to 4 months. 18